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Cardiovascular disease (CVD) is thought to begin early in chronic 
kidney disease (CKD) and to progress rapidly as renal function 
declines, especially on dialysis.[1-3] CVD is the most common cause 
of death among paediatric patients with end-stage renal disease 
(ESRD).[4,5]
Traditional and non-traditional cardiovascular risk factors 
(CVRFs) play an important role in the initiation and progression 
of CVD in children with CKD. Combinations of these risk factors 
could cause accelerated manifestations of cardiac and vascular 
changes in children.[6,7] Traditional CVRFs such as hypertension, 
dyslipidaemia, obesity and hyperglycaemia have been shown to 
be increased even in children with early stages of CKD.[3,6] Non-
traditional CVRFs including anaemia, fluid overload, dysregulated 
mineral bone metabolism (hyperparathyroidism, increased calcium-
phosphate product), hypoalbuminaemia, inflammation (increased 
C-reactive protein and cytokines) and oxidative stress are more 
evident in children with moderate to severe CKD.[1,5-9] Other risk 
factors for CVD are potentially treatment related, such as calcium 
overload from dialysate, calcium-based phosphate binders and 
vitamin D therapy.[10-12]
In adults with ESRD, coronary artery disease and cardiomyo-
pathy are the leading cause of CVD mortality. Children, however, 
die from cardiac arrest, arrhythmia, cardiomyopathy and, rarely, 
myocardial disease.[13,14] Various vascular changes such as athero-
sclerosis, arteriosclerotic lesions (including fibrous or fibroelastic 
intimal thickening), disruption of the internal elastic lamella and 
atheromatous plaques have also been reported in children with 
CKD. [6,8] These vascular changes increase the risk of symptomatic 
CVD later in life.[7]
Objective
To investigate the prevalence of CVRFs and their association with 
mortality in children with CKD.
Methods
This comparative cross-sectional study recruited 106 children with 
CKD being followed up by the Division of Paediatric Nephrology at 
Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani 
Baragwanath Academic Hospital, Johannesburg, South Africa (SA).
Thirty-four patients with CKD I, 36 with CKD II - IV and 36 
with CKD V (dialysis) were recruited consecutively over a 12-month 
period (August 2015 - July 2016). The CKD I group were children 
with a glomerular filtration rate (GFR) of >90 mL/min/1.73m2 (with 
either structural abnormalities or isolated haematuria) with normal 
blood pressure and no proteinuria, the CKD II - IV group were those 
with GFR of 15 - 90 mL/min/1.73m2, and the CKD V group were on 
maintenance haemodialysis and peritoneal dialysis.
Children with known congenital heart disease, diabetes mellitus, 
liver disease, active infection, systemic lupus erythematosus and 
malignancies and those who had had a renal transplant were 
excluded from the study.
All patients had a short demographic and clinical history taken 
along with a physical examination. Routine blood samples for serum 
creatinine, urea, albumin, calcium, phosphorus, parathyroid hormone 
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in the dialysis patients who died.
Conclusions. CVRFs may be present in early CKD, even before the decline in GFR. Routine screening for CVRFs, along with timely 
intervention, may prevent the progression of CVD and mortality later in life.
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(PTH), alkaline phosphatase (ALP), random total cholesterol (TC), 
haemoglobin and C-reactive protein (CRP) were taken, and results 
were retrieved and analysed.
Definitions of terms
• Hypertension. The need for antihypertensive treatment and/or 
according to the ‘Fourth report on the diagnosis, evaluation, and 
treatment of high blood pressure in children and adolescents’.[15]
• Body mass index (BMI). Interpreted according to the World Health 
Organization (WHO) BMI centile for sex and age in children.[16]
• Proteinuria. Urine protein/creatinine ratio >0.02 g/mmol.[17,18]
• Hypercholesterolaemia. Total cholesterol >5.18 mmol/L (>200 mg/
dL).[19]
• Anaemia. Defined based on age according to the Kidney Disease 
Improving Global Outcome (KDIGO) clinical practice guidelines 
for anaemia in CKD.[20]
• Hyperphosphataemia, hypocalcaemia, hypercalcaemia, eleva-
ted calcium-phosphate product (CaXP) and elevated ALP. 
Defined based on age according to the Kidney Disease Outcomes 
Quality Initiative (KDOQI) clinical practice guidelines for bone 
metabolism and disease in children with CKD.[21]
• Hyperparathyroidism. PTH levels above the laboratory normal 
limit (>7.6 pmol/L) in pre-dialysis patients and above nine times 
the upper normal limit (>68.4 pmol/L) in dialysis patients, as 
recommended by KDIGO.[22]
• Hypoalbuminaemia. Serum albumin <35 g/L.[23]
• Elevated CRP. CRP >10 mg/L.[24]
Statistical analysis
All data were collected and managed using Research Electronic 
Data Capture (REDCap).[25] The computer-based statistical package 
Stata 13.1 (StataCorp, USA) was used for the analysis. Continuous 
variables were described using means and standard deviations for 
normally distributed data, and medians and interquartile ranges for 
skewed data. Categorical variables were presented as percentages and 
frequencies. Statistical significance in the prevalence of risk factors 
was tested for using χ2 tests or Fisher’s exact tests, where appropriate. 
Mean/median values for the different groups were compared using 
analysis of variance, Kruskal-Wallis tests, t-tests and Mann-Whitney 
U-tests, depending on the distribution of the data. To compensate for 
multiple testing, Bonferroni-type correction was used to adjust for 
significant levels for the CVRFs as appropriate. Logistic regression 
analysis was used to determine the relationship between mortality and 
CVRFs. All CVRFs were tested using univariate logistic regression 
analysis, and only significant CVRFs (p<0.05) are presented in Table 
3 and included in the multivariate regression model. A confidence 
interval of 95% was used, and p<0.05 was regarded as significant.
Ethics and approval
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M150312) and was 
conducted in compliance with the Helsinki Declaration, Good 
Clinical Practice and the laws and regulations of SA. Informed written 
consent/assent was obtained from participants where appropriate.
Results
The overall median age of the patients was 11 years (range 8 - 14), and 
the male/female ratio was 2.1:1 (Table 1).
Congenital anomalies of the kidneys and urinary tract were the 
most common cause of CKD across all groups, with a total rate of 
47.2% (50/106) observed (Table 1).
A breakdown of the nutritional status of the different groups of 
patients is illustrated in Fig. 1. The majority of the patients (79/106, 
74.8%) were well nourished. Undernutrition was seen only in the 
dialysis group (6/36, 5.6%). Seventeen (16.0%) of the patients were 
classified as overweight (10 CKD I, 7 CKD II - IV) and 3 (2.8%) as 
being obese (1 CKD I, 1 CKD II - IV, 1 CKD V).
Anaemia (42/106, 39.6%) was the most common CVRF, as shown 
in Table 1. Furthermore, anaemia differed significantly between the 
groups and was observed in 2/34 (5.9%) patients with CKD I, 9/36 
(25.0%) of those with CKD II - IV and 31/36 (86.1%) of those with 
CKD V (p<0.001). Hypertension was the second most common 
CVRF, with a significantly higher rate in the dialysis group than in 
the CKD II - IV group (28/36 v. 12/36; p<0.001). Elevated CaXP was 
the CVRF with the overall lowest rate (6.5%) and was found in the 
dialysis group only. Similar trends were observed when the absolute 
values of the various CVRFs were compared across the groups 
(Table 1). The majority of these CVRFs remained significant after 
Bonferroni correction, where p<0.004 was considered significant 
(Table 1).
Over the 12-month duration of the study, we recorded seven 
deaths, all in the dialysis (CKD V) group. Cerebrovascular accident 
(intracranial bleed) associated with severe hypertension accounted 
for the majority (4/7, 57.1%) of the deaths (Fig. 2). Further analysis 
of the dialysis group showed a statistically significant difference 
in the presence of hypercholesterolaemia and hypoalbuminaemia 
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Fig. 1. Nutritional status of the study group. (CKD = chronic kidney disease.)
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Fig. 2. Causes of death. (CVA = cerebrovascular accident.)
712       August 2017, Vol. 107, No. 8
RESEARCH
between the patients who died and those who survived (Table 2). 
Similarly, the patients who died had significantly higher mean levels 
of TC and lower mean levels of albumin when compared with those 
who survived (Table 2). After Bonferroni correction, where p<0.004 
was considered significant, only cholesterol remained significant 
(Table 2). Cholesterol and albumin levels were not associated with 
proteinuria in this subgroup. Univariate logistic regression analysis 
in the dialysis group showed an association of mortality with age, 
serum TC and albumin (Table 3). After adjusting for these three in 
a regression model, we found age to be the most important factor 
associated with mortality in our group of patients (Table 3).
Discussion
The initiation and progression of CVD in children with CKD are 
determined by the presence of single or multiple CVRFs, and CVD 
is thought to begin early and then worsen as renal function declines. 
Our study looked at traditional and non-traditional risk factors for 
CVD, as well as their association with mortality, in children with 
CKD.
The use of the BMI alone in determining the nutritional status 
of CKD patients on dialysis may not be appropriate because of 
interdialytic weight gain and variable dry-weight status.[26] Despite 
these concerns, undernutrition was exclusively seen in the dialysis 
group and we recorded only a single case of overnutrition in the same 
group. A similar finding of undernutrition in advanced CKD has 
been reported in several studies.[27,28] The finding of undernutrition 
in advanced CKD may be explained by low appetite, nausea and 
vomiting, and the effect of enforced dietary restriction resulting in 
caloric deficiency, along with chronic illness, an increased metabolic 
rate, metabolic acidosis and chronic inflammation, in a growing 
child.[29]
Being overweight or obese has been reported to increase the risk 
of having other CVRFs (hypertension, dyslipidaemia and abnormal 
glucose metabolism) when compared with lean patients.[3] It should 
be emphasised at this point that the CKD I group did not have 
proteinuria, so it is unlikely that the presence of patients with 
nephrotic syndrome influenced the rate of hypercholesterolaemia 
in this group. In our study, overnutrition was most common in the 
CKD I and CKD II - IV groups, and we consider that this is a more 
likely explanation for the higher rate of hypercholesterolaemia in the 
CKD I group than in the CKD II - IV group.
Even though hypertension has been reported to be the single most 
important CVRF in CKD,[6,30,31] we found anaemia to be the most 
common CVRF overall in our study, and hypertension to be the 
second most common overall. The high rate of anaemia probably 
reflects the undernutrition reported in the dialysis group, in addition 
to other causes of anaemia in CKD such as declining production of 
erythropoietin, inflammation, severe secondary hyperparathyroidism 
Table 1. Cardiovascular risk factors in all CKD patients
CKD I
(N=34)
CKD II - IV
(N=36)
CKD V (dialysis)
(N=36) p-value
Age (yr), mean (SD) 9.48 (2.85) 11.28 (3.52) 11.86 (3.77) 0.012* 
Sex (M/F) 25:9 26:10 21:15 0.314
Diagnosis, n (%) 0.515
CAKUT 13 (38.2) 19 (52.8) 18 (50.0)
Glomerular disease 12 (35.3) 13 (36.1) 11 (30.6)
Others 9 (26.5) 4 (11.1) 7 (19.4)
MAP (mmHg), median (IQR) 71 (70 - 80) 80 (70 - 86) 91 (81 - 102) <0.001**
Hypertension, n (%) 0 12 (33.3) 28 (77.8) <0.001**
BMI (kg/m2), median (IQR) 17 (15 - 18) 18 (16 - 19) 16 (15 - 18) 0.089
Increased BMI, n (%) 11 (32.4) 8 (22.2) 1(2.8) 0.002**
Hb (g/dL), median (IQR) 13.2 (12.5 - 14.4) 13.4 (12.1 - 14.3) 9.3 (8.1 - 10.6) <0.001**
Anaemia, n (%) 2 (5.9) 9 (25.0) 31 (86.1) <0.001**
CRP (mg/L), median (range) 10† 10 (10 - 61) 10 (10 - 62) 0.003**
Increased CRP, n (%) 0 4 (11.1) 10 (27.8) 0.002**
TC (mmol/L), median (IQR) 3.7 (3.2 - 4.3) 4.2 (3.3 - 4.7) 4.2 (3.3 - 5.7) 0.242
Hypercholesterolaemia, n (%) 4 (11.8) 3 (8.3) 13 (36.1) 0.007*
Albumin (mg/dl), median (IQR) 44 (42 - 45) 44 (41 - 45) 36 (30 - 39) <0.001**
Hypoalbuminaemia, n (%) 0 2 (5.6) 15 (41.7) <0.001**
Phosphate (mmol/L), mean (SD) 1.46 (0.23) 1.37 (0.29) 1.64 (0.52) 0.014*
Hyperphosphataemia, n (%) 4 (11.8) 4 (11.1) 17 (47.2) <0.001**
CaXP, median (IQR) 3.3 (3.0 - 3.6) 3.3 (2.8 - 3.6) 3.5 (2.5 - 4.2) 0.329
Increased CaXP, n (%) 0 0 7 (19.4) ‡ 
ALP (U/L), median (IQR) 245 (212 - 328) 263 (184 - 313) 250 (184 - 484) 0.773
Increased ALP, n (%) 4 (11.8) 9 (25.0) 19 (52.8) 0.001**
PTH (pmol/L), median (IQR) 3.5 (2.7 - 5.3) 6.6 (4.0 - 10.9) 77.9 (17.4 - 144.5) <0.001**
Increased PTH 4/34 (11.8) 15/35 (42.9) 19/36 (52.8) 0.001**
PCR (g/mmol), median (IQR) 0.004 (0.001 - 0.007) 0.030 (0.007 - 0.084) 0.235 (0.050 - 0.930) <0.001**
Proteinuria 0 20/32 (62.5) 8/10 (80.0) <0.001**
CKD = chronic kidney disease; SD = standard deviation; CAKUT = congenital anomalies of the kidney and urinary tract; MAP = mean arterial pressure; IQR = interquartile range;  
BMI = body mass index; Hb = haemoglobin; CRP = C-reactive protein; TC = total cholesterol; CaXP = calcium-phosphate product; ALP = alkaline phosphatase; PTH = parathyroid hormone; 
PCR = urine protein-creatinine ratio.
*Significant at p<0.05. **Significant after Bonferroni correction.
†No range, as all patients had a CRP of 10 mg/L.
‡No statistical analysis applied, because only the dialysis group had increased CaXP.
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leading to myelofibrosis, bone marrow hyporesponsiveness and 
infection.[32] In spite of anaemia being a modifiable risk that can 
be corrected with erythropoiesis-stimulating agents and iron 
supplements, poor absorption of oral iron and poor compliance 
with oral iron due to side-effects such as constipation, diarrhoea and 
abdominal discomfort may have also contributed to the high rate of 
anaemia in our patients.
Across the study groups, except for overnutrition, the rates of 
recorded CVRF were highest in the dialysis group. Previous studies 
have documented a similar pattern in children with CKD.[6,33,34]
Although less common, increased serum TC, phosphate, ALP, 
PTH and anaemia were also seen in the CKD I group. This may be 
attributed to the presence of early changes of CKD even before a 
decline in GFR, onset of proteinuria and hypertension are manifest.
The high death rate recorded over the study period is concerning, 
with severe hypertension and cerebrovascular accident (intracranial 
bleed) accounting for most deaths. Our observations differ from 
the cardiac-related deaths reported in other cohorts of paediatric 
CKD patients on dialysis,[13,14] where cardiac arrest, arrhythmia, 
cardiomyopathy, cardiac failure and myocardial infarction/ischaemia 
were the most common causes of death. This difference may be 
attributed to lack of adequate volume and blood pressure control 
in our dialysis group, leading to severe hypertension. Our findings 
further emphasise the need for adequate blood pressure and fluid 
volume control in our chronic dialysis patients, in addition to control 
of other CVRFs.
Younger age at commencement of dialysis, especially age <1 year, 
has been associated with poorer survival compared with patients who 
are older (>5 years) at the start of dialysis.[13,14] Similarly, we found 
age to be a factor associated with mortality in our group of patients.
The finding of a higher rate of increased TC and decreased 
albumin levels in the dialysis patients who died may be indicative of 
their role in mortality. Even though neither TC nor albumin levels 
were significantly associated with mortality after adjusting for age in 
this study, it is nevertheless still important to correct TC and albumin 
levels in all patients with CKD, as previous studies have implicated 
both of these risk factors as predictors of morbidity and mortality in 
CKD.[23,35-37]
Study strengths and limitations
This is the first African study to look at traditional and non-
traditional risk factors for CVD, as well as their association with 
mortality, among children with CKD. The major limitation is the 
small number of patients in this study and the lack of a disease-free 
Table 2. Mortality and cardiovascular risk factors among dialysis patients
                          Mortality
Yes (N=7) No (N=29) p-value
Age (yr), mean (SD) 7.71 (2.81) 12.86 (3.28) 0.005* 
Duration of dialysis (mo), mean (SD) 11.43 (9.20) 25.72 (36.50) 0.309
BMI (kg/m2), median (IQR) 15 (14 - 16) 17 (15 - 18) 0.031*
MAP (mmHg), mean (SD) 85.86 (16.69) 93.66 (18.61) 0.435
Hypertension, n (%) 5 (71.4) 23 (79.3) 0.639
Hb (g/dL), mean (SD) 8.30 (2.65) 9.46 (1.96) 0.200
Anaemia, n (%) 6 (85.7) 25 (86.2) 1.000
CRP (mg/L), median (IQR) 10 (10 - 29) 10 (10 - 14) 0.441
Increased CRP, n (%) 2 (28.6) 8 (27.6) 1.000
TC (mmol/L), mean (SD) 6.17 (1.44) 4.13 (1.29) 0.001**
Hypercholesterolaemia, n (%) 6 (85.7) 7 (24.1) 0.005*
Albumin (g/L), mean (SD) 29.57 (4.50) 36.04 (5.62) 0.008*
Hypoalbuminaemia, n (%) 6 (85.7) 9 (31.0) 0.013*
Phosphate (mmol/L), mean (SD) 1.57 (0.52) 1.66 (0.53) 0.695
Hyperphosphataemia, n (%) 3 (42.9) 14 (48.3) 1.000
CaXP, mean (SD) 3.31 (1.26) 3.59 (1.37) 0.622
Increased CaXP, n (%) 1 (14.3) 6 (20.7) 1.000
PTH (pmol/L), mean (SD) 71.49 (69.42) 89.19 (74.36) 0.571
Increased PTH, n (%) 3 (42.9) 15 (51.7) 1.000
PCR (g/mmol), median (IQR) 1.46 (1.00 - 1.91) 0.11 (0.03 - 0.35) 0.116
Proteinuria† 2/2 6/8 0.622
SD = standard deviation; BMI = body mass index; IQR = interquartile range; MAP = mean arterial pressure; Hb = haemoglobin; CRP = C-reactive protein; TC = total cholesterol;  
CaXP = calcium-phosphate product; PTH = parathyroid hormone; PCR = urine protein-creatinine ratio.
*Significant at p<0.05. **Significant after Bonferroni correction.
†Not all patients had PCR due to oligoanuria associated with end-stage renal disease.
Table 3. Logistic regression analysis for mortality among dialysis patients
                            Univariate                           Multivariate
OR p-value 95% CI OR p-value 95% CI
Age (yr) 0.62 0.008 0.44 - 0.88 0.67 0.058 0.44 - 1.01
TC (mmol/L) 2.83 0.008 1.31 - 6.14 2.32 0.119 0.81 - 6.68
Albumin (mg/dL) 0.81 0.021 0.68 - 0.97 0.85 0.194 0.66 - 1.09
OR = odds ratio; CI = confidence interval; TC = total cholesterol.
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control group for comparison. Another limitation is that random and 
not fasting cholesterol was measured.
Conclusions
CVRFs may be present in early CKD, even before the decline in 
GFR is detected, and tend to worsen as renal function deteriorates, 
especially in patients on dialysis. These risk factors play an important 
role in the morbidity and mortality associated with CVD in children 
with CKD. Routine screening for these CVRFs, along with timely 
intervention, may go a long way towards preventing the progression 
of CVD and cardiac-related mortality later in life.
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